The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical activity of novel targeting of S100A9 with tasquinimod for relapsed and refractory multiple myeloma (RRMM).
 
Dan Vogl
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Janssen; Sanofi; Takeda
Research Funding - Active Biotech; Takeda
 
Yulia Nefedova
Research Funding - Active Biotech
 
E. Paul Wileyto
No Relationships to Disclose
 
Sara Whittington
No Relationships to Disclose
 
Cynthia Diaczynsky
No Relationships to Disclose
 
Chau Nguyen
No Relationships to Disclose
 
Inna Strakovsky
No Relationships to Disclose
 
Eva Bondesson
Employment - Active Biotech
 
Helen Tuvesson
Employment - Active Biotech
 
Erik Vahtola
Employment - Active Biotech
 
Adam Cohen
Consulting or Advisory Role - Abbvie; Arcellx; Bristol Meyers Squibb; GlaxoSmithKline; Ichnos Sciences; ITeos Therapeutics; Janssen Oncology; Novartis; Pfizer; Roche/Genentech; Takeda
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Patents related to CAR T cells and biomarkers of Cytokine Release Syndrome
Travel, Accommodations, Expenses - Abbvie; Bristol-Myers Squibb; Ichnos Sciences; Janssen Oncology; Janssen Oncology
 
Sandra Susanibar-Adaniya
No Relationships to Disclose
 
Adam Waxman
No Relationships to Disclose
 
Shivani Kapur
No Relationships to Disclose
 
Alfred Garfall
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb/Celgene; CDR-Life; GlaxoSmithKline; Janssen Oncology; Novartis; Regeneron; Smart Immune
Research Funding - crispr therapeutics (Inst); Janssen Oncology (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Patent in the field of CAR T cell therapy
Travel, Accommodations, Expenses - Janssen
 
Edward Stadtmauer
No Relationships to Disclose